<?xml version="1.0" encoding="UTF-8" standalone="yes"?>

<!-- Copyright (c) 2004-2026 Broad Institute, Inc., Massachusetts Institute of Technology, and Regents of the University of California.  All rights reserved.
     See license terms at www.gsea-msigdb.org/gsea/license_terms_list. Please note that certain gene sets have special access terms.
-->
<MSIGDB BUILD_DATE="Jan 29, 2026" VERSION="2026.1.Hs" NAME="export">
    <GENESET STANDARD_NAME="TCGA_GLIOBLASTOMA_COPY_NUMBER_DN" SYSTEMATIC_NAME="M5520" HISTORICAL_NAMES="" PMID="18772890" AUTHORS="Cancer Genome Atlas Research Network" GEOID="GSE11233" EXACT_SOURCE="Table 2S: reduced expression and deletion" GENESET_LISTING_URL="" EXTERNAL_DETAILS_URL="" CHIP="HUMAN_GENE_SYMBOL" CONTRIBUTOR="Jessica Robertson" CONTRIBUTOR_ORG="MSigDB Team" DESCRIPTION_BRIEF="Genes down-regulated and displaying decreased copy number in glioblastoma samples." DESCRIPTION_FULL="Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas--the most common type of adult brain cancer--and nucleotide sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer." TAGS="" MEMBERS="ATAD1,C13orf1,CAB39L,CDADC1,CDKN2A,CDKN2B,CDKN2C,EBPL,ENO1,EVI2B,FAF1,FNDC3A,H6PD,hsa-mir-15a,KCNRG,KPNA3,MIR34A,NF1,OMG,PARK2,PHF11,PTEN,QKI,RB1,RCBTB1,RCBTB2,RERE,SETDB2,SLC45A1,SPSB1,TRIM13" MEMBERS_SYMBOLIZED="ATAD1,CAB39L,CDADC1,CDKN2A,CDKN2B,CDKN2C,EBPL,ENO1,EVI2B,FAF1,FNDC3A,H6PD,KCNRG,KPNA3,MIR15A,MIR34A,NF1,OMG,PHF11,PRKN,PTEN,QKI,RB1,RCBTB1,RCBTB2,RERE,SETDB2,SLC45A1,SPRYD7,SPSB1,TRIM13" MEMBERS_EZID="10206,1029,1030,1031,1102,11124,2023,2124,22862,283518,3839,406948,407040,473,4763,4974,50651,5071,51131,55213,57213,5728,5925,80176,81602,81617,83852,84650,84896,9444,9563" MEMBERS_MAPPING="ATAD1,ATAD1,84896|C13orf1,SPRYD7,57213|CAB39L,CAB39L,81617|CDADC1,CDADC1,81602|CDKN2A,CDKN2A,1029|CDKN2B,CDKN2B,1030|CDKN2C,CDKN2C,1031|EBPL,EBPL,84650|ENO1,ENO1,2023|EVI2B,EVI2B,2124|FAF1,FAF1,11124|FNDC3A,FNDC3A,22862|H6PD,H6PD,9563|KCNRG,KCNRG,283518|KPNA3,KPNA3,3839|MIR34A,MIR34A,407040|NF1,NF1,4763|OMG,OMG,4974|PARK2,PRKN,5071|PHF11,PHF11,51131|PTEN,PTEN,5728|QKI,QKI,9444|RB1,RB1,5925|RCBTB1,RCBTB1,55213|RCBTB2,RCBTB2,1102|RERE,RERE,473|SETDB2,SETDB2,83852|SLC45A1,SLC45A1,50651|SPSB1,SPSB1,80176|TRIM13,TRIM13,10206|hsa-mir-15a,MIR15A,406948" FILTERED_BY_SIMILARITY="" FOUNDER_NAMES="" REFINEMENT_DATASETS="" VALIDATION_DATASETS="" CATEGORY_CODE="C2" ORGANISM="Homo sapiens" SUB_CATEGORY_CODE="CGP"/>
</MSIGDB>
